Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
Authors
Takeshi Yamada
Nippon Medical School Hospital, Bunkyo-Ku, Japan;
Takeshi Yamada , Nobuhisa Matsuhashi , Takao Takahashi , Keiji Hirata , Takeshi Nagasaka , Yuki Nakamura , Kazuhiro Sakamoto , Keiji Koda , Kazuhiro Hiramatsu , Hiroshi Matsuoka , Hidekazu Kuramochi , Hideyuki Ishida , Kozo Kataoka , Hajime Yokomizo , Yoshinori Kagawa , Mitsukuni Suenaga , Ryo Ohta , Akihisa Matsuda , Hiroshi Yoshida
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
000031177
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 219)
DOI
10.1200/JCO.2023.41.4_suppl.219
Abstract #
219
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
First Author: Emily Harrold
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2022 ASCO Gastrointestinal Cancers Symposium
An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17).
First Author: Naoki Izawa